Atrium Therapeutics, Inc. Common Stock (RNA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $162.00M
Last updated: Nov 17, 2026 at 11:06 AM ET
Atrium Therapeutics, Inc. Common Stock (RNA) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Atrium Therapeutics, Inc. Common Stock reported EPS of -$0.25, above the -$1.15 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RNA's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
Earnings History
Of the 31 quarters below that had an estimate, RNA beat 17, missed 13 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $15.32M, up 22.9% from $12.47M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.25 | -$1.15 | N/A | +78.26% | Beat | N/A | 2 | 1 up, 0 down | Nov 12, 2026 | $15.32M |
| Jun 30, 2026 | -$1.18 | -$0.64 | -$0.64 - -$0.64 | -84.38% | Miss | N/A | 1 | 0 up, 0 down | Aug 13, 2026 | $3.00M |
| Mar 31, 2026 | -$0.97 | -$1.05 | -$1.05 - -$1.05 | +7.62% | Beat | N/A | 1 | 0 up, 0 down | May 14, 2026 | $19.64M |
| Dec 31, 2025 | -$1.59 | -$1.26 | -$1.44 - -$0.96 | -26.19% | Miss | N/A | 11 | 0 up, 1 down | Feb 26, 2026 | $859000 |
| Sep 30, 2025 | -$1.27 | -$1.10 | -$1.27 - -$0.61 | -15.45% | Miss | N/A | 13 | 2 up, 0 down | Nov 10, 2025 | $12.47M |
| Jun 30, 2025 | -$1.21 | -$0.96 | -$1.33 - -$0.55 | -26.04% | Miss | N/A | 15 | 7 up, 3 down | Aug 7, 2025 | $3.85M |
| Mar 31, 2025 | -$0.90 | -$0.88 | -$1.07 - -$0.55 | -2.27% | Miss | N/A | 11 | 0 up, 1 down | May 8, 2025 | $1.57M |
| Dec 31, 2024 | -$0.80 | -$0.78 | -$0.90 - -$0.57 | -2.45% | Miss | N/A | 9 | 5 up, 4 down | Feb 26, 2025 | $2.97M |
| Sep 30, 2024 | -$0.65 | -$0.72 | -$0.94 - -$0.46 | +9.72% | Beat | N/A | 10 | 1 up, 0 down | Nov 7, 2024 | $2.34M |
| Jun 30, 2024 | -$0.65 | -$0.78 | -$0.94 - -$0.60 | +16.67% | Beat | N/A | 8 | 0 up, 0 down | Aug 9, 2024 | $2.04M |
| Mar 31, 2024 | -$0.79 | -$0.88 | -$0.95 - -$0.67 | +10.23% | Beat | N/A | 7 | 0 up, 0 down | May 9, 2024 | $3.54M |
| Dec 31, 2023 | -$0.79 | -$0.66 | -$0.88 - $0.07 | -19.70% | Miss | N/A | 6 | 0 up, 0 down | Feb 28, 2024 | $2.19M |
| Sep 30, 2023 | -$0.71 | -$0.75 | -$0.80 - -$0.73 | +5.33% | Beat | N/A | 5 | 0 up, 0 down | Nov 8, 2023 | $2.82M |
| Jun 30, 2023 | -$0.66 | -$0.79 | -$0.88 - -$0.73 | +16.46% | Beat | N/A | 7 | 0 up, 0 down | Aug 8, 2023 | $2.32M |
| Mar 31, 2023 | -$0.74 | -$0.86 | -$1.05 - -$0.69 | +13.95% | Beat | N/A | 7 | 0 up, 0 down | May 9, 2023 | $2.23M |
| Dec 31, 2022 | -$0.88 | -$0.89 | -$1.07 - -$0.75 | +1.12% | Beat | N/A | 7 | 0 up, 0 down | Feb 28, 2023 | $2.77M |
| Sep 30, 2022 | -$0.82 | -$0.93 | -$1.00 - -$0.84 | +11.83% | Beat | N/A | 7 | 0 up, 0 down | Nov 8, 2022 | $2.48M |
| Jun 30, 2022 | -$0.92 | -$0.77 | -$0.84 - -$0.67 | -19.48% | Miss | N/A | 7 | 0 up, 0 down | Aug 9, 2022 | $2.18M |
| Mar 31, 2022 | -$0.71 | -$0.83 | -$1.00 - -$0.60 | +14.46% | Beat | N/A | 5 | 0 up, 0 down | May 10, 2022 | $1.79M |
| Dec 31, 2021 | -$0.82 | -$0.70 | -$0.73 - -$0.63 | -17.14% | Miss | N/A | 4 | 0 up, 0 down | Mar 1, 2022 | $1.85M |
| Sep 30, 2021 | -$0.68 | -$0.68 | -$0.76 - -$0.60 | 0.00% | In line | N/A | 4 | N/A | Nov 9, 2021 | $2.16M |
| Jun 30, 2021 | -$0.70 | -$0.71 | -$0.84 - -$0.63 | +1.41% | Beat | N/A | 4 | N/A | Aug 9, 2021 | $2.61M |
| Mar 31, 2021 | -$0.64 | -$0.56 | -$0.63 - -$0.47 | -14.29% | Miss | N/A | 3 | N/A | May 12, 2021 | $2.70M |
| Dec 31, 2020 | -$0.43 | -$0.34 | -$0.38 - -$0.29 | -26.47% | Miss | N/A | 4 | N/A | Mar 15, 2021 | $2.14M |
| Sep 30, 2020 | -$0.31 | -$0.43 | -$0.55 - -$0.27 | +27.91% | Beat | N/A | 4 | N/A | Nov 10, 2020 | $1.75M |
| Jun 30, 2020 | -$1.23 | -$0.36 | N/A | -241.67% | Miss | N/A | N/A | N/A | Aug 10, 2020 | $1.54M |
| Mar 31, 2020 | -$0.56 | -$1.58 | N/A | +64.56% | Beat | N/A | N/A | N/A | Jun 8, 2020 | $1.36M |
| Sep 30, 2014 | -$0.29 | -$0.23 | N/A | -26.09% | Miss | N/A | N/A | N/A | Sep 30, 2014 | N/A |
| Jun 30, 2014 | -$0.22 | -$0.25 | N/A | +12.00% | Beat | N/A | N/A | N/A | Jun 30, 2014 | $164000 |
| Mar 31, 2014 | $0.19 | -$0.03 | N/A | +733.33% | Beat | N/A | N/A | N/A | Mar 31, 2014 | $20.65M |
| Dec 31, 2013 | -$0.11 | -$0.12 | N/A | +8.33% | Beat | N/A | N/A | N/A | Dec 31, 2013 | $3.64M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$4.97, after -$2.89 the year before. It was -$0.11 for the year ended Dec 31, 2013, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$4.97 | N/A |
| Dec 31, 2024 | -$2.89 | N/A |
| Dec 31, 2023 | -$2.90 | N/A |
| Dec 31, 2022 | -$3.33 | N/A |
| Dec 31, 2021 | -$2.84 | N/A |
| Dec 31, 2020 | -$2.85 | N/A |
| Dec 31, 2013 | -$0.11 | N/A |
Frequently Asked Questions About RNA
Did RNA beat earnings estimates last quarter?
Yes. Atrium Therapeutics, Inc. Common Stock reported EPS of -$0.25 for the quarter ended Sep 30, 2026, above the -$1.15 estimate, a 78.26% surprise.
What EPS do analysts expect from RNA next quarter?
The consensus EPS estimate for Atrium Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$1.26 from 6 analysts, with estimates from -$1.72 to -$0.39.
How often does RNA beat earnings estimates?
Atrium Therapeutics, Inc. Common Stock beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -8.86%.
RNA pages: Overview, Earnings, Forecast, Financials, Competitors